Journal
EMERGING INFECTIOUS DISEASES
Volume 27, Issue 12, Pages 3178-3180Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2712.211772
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [U01AI151797]
- National Research Council of Thailand [N35A640037]
Ask authors/readers for more resources
In vitro testing of serum samples from CoronaVac vaccine recipients showed that neutralizing antibodies provided short-term protection against the original virus strain and limited protection against variants of concern. These findings support the use of vaccine boosters, particularly in regions where variants of concern are circulating.
In vitro determination of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies induced in serum samples from recipients of the CoronaVac vaccine showed a short protection period against the original virus strain and limited protection against variants of concern. These data provide support for vaccine boosters, especially variants of concern circulate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available